
Annette G Beck-Sickinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9364927/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Orthogonal Peptideâ€Templated Labeling Elucidates Lateral ET _A R/ET _B R Proximity and Reveals Altered Downstream Signaling. ChemBioChem, 2022, 23, .	2.6	4
2	Binding of Natural Peptide Ligands to the Neuropeptide Y ₅ Receptor. Angewandte Chemie - International Edition, 2022, 61, e202108738.	13.8	6
3	Binding of Natural Peptide Ligands to the Neuropeptide Y5 Receptor. Angewandte Chemie, 2022, 134, e202108738.	2.0	0
4	Chemerin– exploring a versatile adipokine. Biological Chemistry, 2022, 403, 625-642.	2.5	17
5	Analytik synthetischer Peptide. , 2022, , 643-657.		0
6	The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors. Molecules, 2022, 27, 210.	3.8	10
7	Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. Science Advances, 2022, 8, eabm1232.	10.3	22
8	Shuttling of Peptideâ€Ðrug Conjugates by G Protein oupled Receptors Is Significantly Improved by Pulsed Application. ChemMedChem, 2021, 16, 164-178.	3.2	7
9	Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity. Metabolism: Clinical and Experimental, 2021, 116, 154438.	3.4	17
10	Live cell PNA labelling enables erasable fluorescence imaging of membrane proteins. Nature Chemistry, 2021, 13, 15-23.	13.6	48
11	Determination of G-protein–coupled receptor oligomerization by molecular brightness analyses in single cells. Nature Protocols, 2021, 16, 1419-1451.	12.0	25
12	Strategies for Site‧pecific Labeling of Receptor Proteins on the Surfaces of Living Cells by Using Genetically Encoded Peptide Tags. ChemBioChem, 2021, 22, 1717-1732.	2.6	14
13	Highly Selective Y ₄ Receptor Antagonist Binds in an Allosteric Binding Pocket. Journal of Medicinal Chemistry, 2021, 64, 2801-2814.	6.4	13
14	Structural basis for ligand recognition of the neuropeptide Y Y2 receptor. Nature Communications, 2021, 12, 737.	12.8	24
15	Cyclic Analogues of the Chemerin C-Terminus Mimic a Loop Conformation Essential for Activating the Chemokine-like Receptor 1. Journal of Medicinal Chemistry, 2021, 64, 3048-3058.	6.4	11
16	Photoinduced receptor confinement drives ligand-independent GPCR signaling. Science, 2021, 371, .	12.6	17
17	Development of a ghrelin receptor inverse agonist for positron emission tomography. Oncotarget, 2021, 12, 450-474.	1.8	3
18	The ring size of monocyclic ETâ€1 controls selectivity and signaling efficiency at both endothelin receptor subtypes. Journal of Peptide Science, 2021, 27, e3325.	1.4	4

#	Article	IF	CITATIONS
19	Arrestin-dependent internalization of rhodopsin-like G protein-coupled receptors. Biological Chemistry, 2021, .	2.5	4
20	Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite. Journal of Medicinal Chemistry, 2021, 64, 9484-9495.	6.4	8
21	Introducing… Advisory Editors and New Author Profiles at <i>Angewandte Chemie</i> . Angewandte Chemie - International Edition, 2021, 60, 16720-16722.	13.8	4
22	Introducing… Advisory Editors and New Author Profiles at <i>Angewandte Chemie</i> . Angewandte Chemie, 133, 16856-16858.	2.0	2
23	Ligand-binding and -scavenging of the chemerin receptor GPR1. Cellular and Molecular Life Sciences, 2021, 78, 6265-6281.	5.4	12
24	Cyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment. Cancers, 2021, 13, 3788.	3.7	8
25	Improvement of wound healing by the development of ECM-inspired biomaterial coatings and controlled protein release. Biological Chemistry, 2021, 402, 1271-1288.	2.5	10
26	Cleavage of the vaspin N-terminus releases cell-penetrating peptides that affect early stages of adipogenesis and inhibit lipolysis in mature adipocytes. Adipocyte, 2021, 10, 216-231.	2.8	5
27	Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell Research, 2021, 31, 1176-1189.	12.0	40
28	Protease-Triggered Release of Stabilized CXCL12 from Coated Scaffolds in an Ex Vivo Wound Model. Pharmaceutics, 2021, 13, 1597.	4.5	3
29	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	11
30	Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy. Journal of Medicinal Chemistry, 2020, 63, 2358-2371.	6.4	38
31	Biased agonists at the human Y1 receptor lead to prolonged membrane residency and extended receptor G protein interaction. Cellular and Molecular Life Sciences, 2020, 77, 4675-4691.	5.4	7
32	Tuning a modular system – synthesis and characterisation of a boron-rich <i>s</i> -triazine-based carboxylic acid and amine bearing a galactopyranosyl moiety. Dalton Transactions, 2020, 49, 57-69.	3.3	8
33	A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. Journal of Organic Chemistry, 2020, 85, 1446-1457.	3.2	30
34	NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression. Molecular Metabolism, 2020, 31, 163-180.	6.5	17
35	Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Frontiers in Chemistry, 2020, 8, 571.	3.6	143
36	The Conformational Equilibrium of the Neuropeptide Y2 Receptor in Bilayer Membranes. Angewandte Chemie - International Edition, 2020, 59, 23854-23861.	13.8	29

#	Article	IF	CITATIONS
37	Peptideâ€mediated surface coatings for the release of woundâ€healing cytokines. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 1738-1748.	2.7	9
38	Probing the Y2 Receptor on Transmembrane, Intra- and Extra-Cellular Sites for EPR Measurements. Molecules, 2020, 25, 4143.	3.8	5
39	The Dynamics of the Neuropeptide Y Receptor Type 1 Investigated by Solid-State NMR and Molecular Dynamics Simulation. Molecules, 2020, 25, 5489.	3.8	9
40	Targeting of peptideâ€binding receptors on cancer cells with peptideâ€drug conjugates. Peptide Science, 2020, 112, e24171.	1.8	38
41	Advanced 96-microtiter plate based bioelectrochemical platform reveals molecular short cut of electron flow in cytochrome P450 enzyme. Lab on A Chip, 2020, 20, 1449-1460.	6.0	11
42	Adrenomedullin – Current perspective on a peptide hormone with significant therapeutic potential. Peptides, 2020, 131, 170347.	2.4	23
43	A Venomics Approach Coupled to High-Throughput Toxin Production Strategies Identifies the First Venom-Derived Melanocortin Receptor Agonists. Journal of Medicinal Chemistry, 2020, 63, 8250-8264.	6.4	13
44	From Scientists to Scientists—Moving <i>Angewandte</i> into the Future. Angewandte Chemie, 2020, 132, 12648-12649.	2.0	4
45	From Scientists to Scientists—Moving <i>Angewandte</i> into the Future. Angewandte Chemie - International Edition, 2020, 59, 12548-12549.	13.8	15
46	An MRM-Based Multiplexed Quantification Assay for Human Adipokines and Apolipoproteins. Molecules, 2020, 25, 775.	3.8	9
47	Multifunctional coatings combining bioactive peptides and affinity-based cytokine delivery for enhanced integration of degradable vascular grafts. Biomaterials Science, 2020, 8, 1734-1747.	5.4	18
48	Unusually persistent Gαi-signaling of the neuropeptide Y2 receptor depletes cellular Gi/o pools and leads to a Gi-refractory state. Cell Communication and Signaling, 2020, 18, 49.	6.5	11
49	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. EJNMMI Research, 2020, 10, 16.	2.5	11
50	Half-Life Extending Modifications of Peptide YY _{3–36} Direct Receptor-Mediated Internalization. Molecular Pharmaceutics, 2019, 16, 3665-3677.	4.6	18
51	Modular triazine-based carborane-containing carboxylic acids – synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks. Dalton Transactions, 2019, 48, 10834-10844.	3.3	21
52	Modulation of Human CXCL12 Binding Properties to Glycosaminoglycans To Enhance Chemotactic Gradients. ACS Biomaterials Science and Engineering, 2019, 5, 5128-5138.	5.2	10
53	Energetic electron assisted synthesis of highly tunable temperature-responsive collagen/elastin gels for cyclic actuation: macroscopic switching and molecular origins. Scientific Reports, 2019, 9, 12363.	3.3	8
54	Structural investigations of cell-free expressed G protein-coupled receptors. Biological Chemistry, 2019, 401, 97-116.	2.5	7

#	Article	IF	CITATIONS
55	Endothelialization of Titanium Surfaces by Bioinspired Cell Adhesion Peptide Coatings. Bioconjugate Chemistry, 2019, 30, 2664-2674.	3.6	20
56	Syntheses of defined sulfated oligohyaluronans reveal structural effects, diversity and thermodynamics of GAG–protein binding. Chemical Science, 2019, 10, 866-878.	7.4	30
57	Chemical modification of neuropeptide Y for human Y ₁ receptor targeting in health and disease. Biological Chemistry, 2019, 400, 299-311.	2.5	11
58	Adrenomedullin disulfide bond mimetics uncover structural requirements for AM ₁ receptor activation. Journal of Peptide Science, 2019, 25, e3147.	1.4	8
59	Structural Model of Ghrelin Bound to its G Protein-Coupled Receptor. Structure, 2019, 27, 537-544.e4.	3.3	47
60	Cell-Free Expression and Photo-Crosslinking of the Human Neuropeptide Y2 Receptor. Frontiers in Pharmacology, 2019, 10, 176.	3.5	7
61	Identification and stabilization of a highly selective gastrinâ€releasing peptide receptor agonist. Journal of Peptide Science, 2019, 25, e3224.	1.4	15
62	Structural basis of ligand binding modes at the neuropeptide YY1 receptor. Nature, 2018, 556, 520-524.	27.8	100
63	G Protein Preassembly Rescues Efficacy of W ^{6.48} Toggle Mutations in Neuropeptide Y ₂ Receptor. Molecular Pharmacology, 2018, 93, 387-401.	2.3	22
64	Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics. Bioorganic and Medicinal Chemistry, 2018, 26, 2759-2765.	3.0	214
65	The effect of interleukinâ€8 truncations on its interactions with glycosaminoglycans. Biopolymers, 2018, 109, e23103.	2.4	19
66	Time-Resolved Tracking of Separately Internalized Neuropeptide Y ₂ Receptors by Two-Color Pulse-Chase. ACS Chemical Biology, 2018, 13, 618-627.	3.4	17
67	Surface-Binding Peptide Facilitates Electricity-Driven NADPH-Free Cytochrome P450 Catalysis. ChemCatChem, 2018, 10, 487-487.	3.7	1
68	Surfaceâ€Binding Peptide Facilitates Electricityâ€Driven NADPHâ€Free Cytochrome P450 Catalysis. ChemCatChem, 2018, 10, 525-530.	3.7	17
69	Conformation and Aggregation of Selectively PEGylated and Lipidated Gastric Peptide Hormone Human PYY _{3–36} . Biomacromolecules, 2018, 19, 4320-4332.	5.4	17
70	A stable <i>meta</i> â€carborane enables the generation of boronâ€rich peptide agonists targeting the ghrelin receptor. Journal of Peptide Science, 2018, 24, e3119.	1.4	36
71	The Impact of Adrenomedullin Thr22 on Selectivity within the Calcitonin Receptorâ€like Receptor/Receptor Activityâ€Modifying Protein System. ChemMedChem, 2018, 13, 1797-1805.	3.2	7
72	Different mode of arrestin-3 binding at the human Y 1 and Y 2 receptor. Cellular Signalling, 2018, 50, 58-71.	3.6	23

#	Article	IF	CITATIONS
73	Carbaboranylation of Truncated Câ€Terminal Neuropeptideâ€Y Analogue Leads to Full hY ₁ Receptor Agonism. ChemBioChem, 2018, 19, 2300-2306.	2.6	10
74	Adrenomedullin – new perspectives of a potent peptide hormone. Journal of Peptide Science, 2017, 23, 472-485.	1.4	59
75	C-terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment. Cellular Signalling, 2017, 29, 233-239.	3.6	7
76	Expression, Functional Characterization, and Solid-State NMR Investigation of the G Protein-Coupled GHS Receptor in Bilayer Membranes. Scientific Reports, 2017, 7, 46128.	3.3	20
77	Identification and Characterization of the First Selective Y ₄ Receptor Positive Allosteric Modulator. Journal of Medicinal Chemistry, 2017, 60, 7605-7612.	6.4	11
78	A Deep Hydrophobic Binding Cavity is the Main Interaction for Different Y ₂ R Antagonists. ChemMedChem, 2017, 12, 75-85.	3.2	11
79	Multifunctional biomaterial coatings: synthetic challenges and biological activity. Biological Chemistry, 2017, 398, 3-22.	2.5	46
80	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. International Journal of Molecular Sciences, 2017, 18, 768.	4.1	10
81	Improved in Vitro Folding of the Y2 G Protein-Coupled Receptor into Bicelles. Frontiers in Molecular Biosciences, 2017, 4, 100.	3.5	22
82	Discovery of Small-Molecule Modulators of the Human Y4 Receptor. PLoS ONE, 2016, 11, e0157146.	2.5	11
83	Inhibition of Kallikreinâ€Related Peptidases 7 and 5 by Grafting Serpin Reactiveâ€Center Loop Sequences onto Sunflower Trypsin Inhibitorâ€1 (SFTIâ€1). ChemBioChem, 2016, 17, 719-726.	2.6	32
84	Multifunctional Coating Improves Cell Adhesion on Titanium by using Cooperatively Acting Peptides. Angewandte Chemie - International Edition, 2016, 55, 4826-4830.	13.8	61
85	Multifunktionale Beschichtung verbessert Zelladhäion auf Titan durch kooperativ wirkende Peptide. Angewandte Chemie, 2016, 128, 4907-4911.	2.0	5
86	Double Methotrexate-Modified Neuropeptide Y Analogues Express Increased Toxicity and Overcome Drug Resistance in Breast Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 3409-3417.	6.4	33
87	Different Y2 receptor antagonists share the same deep, hydrophobic binding pocket. Neuropeptides, 2016, 55, 16-17.	2.2	0
88	On-resin Diels–Alder reaction with inverse electron demand: an efficient ligation method for complex peptides with a varying spacer to optimize cell adhesion. Organic and Biomolecular Chemistry, 2016, 14, 4809-4816.	2.8	16
89	Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. Endocrinology, 2016, 157, 3482-3492.	2.8	58
90	Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential. ChemMedChem, 2016, 11, 2378-2384.	3.2	26

#	Article	lF	CITATIONS
91	Peptide mini-scaffold facilitates JNK3 activation in cells. Scientific Reports, 2016, 6, 21025.	3.3	50
92	The structural investigation of glycosaminoglycan binding to CXCL12 displays distinct interaction sites. Glycobiology, 2016, 26, 1209-1221.	2.5	27
93	Influence of distinct motifs within the carboxyl-terminusof the human neuropeptide Y4 receptor on internalization and arrestin3 recruitment. Neuropeptides, 2016, 55, 23.	2.2	0
94	Adrenomedullin 2.0: Adjusting Key Levers for Metabolic Stability. Journal of Medicinal Chemistry, 2016, 59, 5695-5705.	6.4	21
95	Charge ompensated Metallacarborane Building Blocks for Conjugation with Peptides. ChemBioChem, 2016, 17, 308-317.	2.6	28
96	Anti-Inflammatory Action of Keratinocyte-Derived Vaspin. American Journal of Pathology, 2016, 186, 639-651.	3.8	33
97	Peptide-Mediated Specific Immobilization of Catalytically Active Cytochrome P450 BM3 Variant. Bioconjugate Chemistry, 2016, 27, 1090-1097.	3.6	19
98	Câ€ŧerminus of a hexapeptidic ghrelin receptor inverse agonist can switch peptide behavior from inverse agonism to agonism. Biopolymers, 2016, 106, 101-108.	2.4	3
99	A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways. Journal of Biological Chemistry, 2016, 291, 7809-7820.	3.4	29
100	Short-range cytokine gradients to mimic paracrine cell interactions in vitro. Journal of Controlled Release, 2016, 224, 59-68.	9.9	12
101	Peptide-tags for site-specific protein labelling in vitro and in vivo. Molecular BioSystems, 2016, 12, 1731-1745.	2.9	152
102	Fluorescently labeled adrenomedullin allows real-time monitoring of adrenomedullin receptor trafficking in living cells. Journal of Peptide Science, 2015, 21, 905-912.	1.4	23
103	Unwinding of the Câ€Terminal Residues of Neuropeptideâ€Y is critical for Y ₂ Receptor Binding and Activation. Angewandte Chemie - International Edition, 2015, 54, 7446-7449.	13.8	74
104	Controlling Toxicity of Peptide–Drug Conjugates by Different Chemical Linker Structures. ChemMedChem, 2015, 10, 804-814.	3.2	34
105	Integrating Solid-State NMR and Computational Modeling to Investigate the Structure and Dynamics of Membrane-Associated Ghrelin. PLoS ONE, 2015, 10, e0122444.	2.5	14
106	Carbaboranes – more than just phenyl mimetics. Pure and Applied Chemistry, 2015, 87, 163-171.	1.9	21
107	High metabolic in vivo stability and bioavailability of a palmitoylated ghrelin receptor ligand assessed by mass spectrometry. Bioorganic and Medicinal Chemistry, 2015, 23, 3925-3932.	3.0	18
108	Quantitative impedimetric NPY-receptor activation monitoring and signal pathway profiling in living cells. Biosensors and Bioelectronics, 2015, 67, 386-393.	10.1	9

#	Article	IF	CITATIONS
109	Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation. Molecular Metabolism, 2015, 4, 210-221.	6.5	17
110	Drug delivery and release systems for targeted tumor therapy. Journal of Peptide Science, 2015, 21, 186-200.	1.4	84
111	Recombinant expression and characterization of biologically active protein delta homolog 1. Protein Expression and Purification, 2015, 110, 72-78.	1.3	3
112	Synthesis and <i>in Vitro</i> and <i>in Vivo</i> Evaluation of an ¹⁸ F-Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET. Molecular Pharmaceutics, 2015, 12, 1121-1130.	4.6	34
113	A cleavable cytolysin–neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action. Journal of Controlled Release, 2015, 209, 170-178.	9.9	11
114	Intracellular Trafficking of Neuropeptide Y Receptors. Progress in Molecular Biology and Translational Science, 2015, 132, 73-96.	1.7	6
115	Rational Design of Dual Peptides Targeting Ghrelin and Y ₂ Receptors to Regulate Food Intake and Body Weight. Journal of Medicinal Chemistry, 2015, 58, 4180-4193.	6.4	9
116	Rapid Covalent Fluorescence Labeling of Membrane Proteins on Live Cells via Coiled-Coil Templated Acyl Transfer. Bioconjugate Chemistry, 2015, 26, 2106-2117.	3.6	31
117	Bioorthogonal Labeling of Ghrelin Receptor to Facilitate Studies of Ligand-Dependent Conformational Dynamics. Chemistry and Biology, 2015, 22, 1431-1436.	6.0	17
118	Ubiquitin is a versatile scaffold protein for the generation of molecules with <i>de novo</i> binding and advantageous drugâ€like properties. FEBS Open Bio, 2015, 5, 579-593.	2.3	11
119	Receptorâ€Mediated Uptake of Boronâ€Rich Neuropeptideâ€Y Analogues for Boron Neutron Capture Therapy. ChemMedChem, 2015, 10, 164-172.	3.2	52
120	Peptides as Modulators of Serpin Action. , 2015, , 29-45.		2
121	Automated solid-phase peptide synthesis to obtain therapeutic peptides. Beilstein Journal of Organic Chemistry, 2014, 10, 1197-1212.	2.2	179
122	Peptide Modifications Differentially Alter G Proteinâ€Coupled Receptor Internalization and Signaling Bias. Angewandte Chemie - International Edition, 2014, 53, 10067-10071.	13.8	39
123	Peptideâ€Templated Acyl Transfer: A Chemical Method for the Labeling of Membrane Proteins on Live Cells. Angewandte Chemie - International Edition, 2014, 53, 10237-10241.	13.8	71
124	Pancreatic Polypeptide Is Recognized by Two Hydrophobic Domains of the Human Y4 Receptor Binding Pocket. Journal of Biological Chemistry, 2014, 289, 5846-5859.	3.4	28
125	Peptide Modifications Differentially Alter G Protein oupled Receptor Internalization and Signaling Bias. Angewandte Chemie, 2014, 126, 10231-10235.	2.0	3
126	Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes. Cellular Signalling, 2014, 26, 1523-1531.	3.6	43

#	Article	IF	CITATIONS
127	Slime protein profiling: a non-invasive tool for species identification in Onychophora (velvet worms). Journal of Zoological Systematics and Evolutionary Research, 2014, 52, 265-272.	1.4	22
128	Position and Length of Fatty Acids Strongly Affect Receptor Selectivity Pattern of Human Pancreatic Polypeptide Analogues. ChemMedChem, 2014, 9, 2463-2474.	3.2	20
129	Proteintemplatâ€vermittelter Acyltransfer: eine chemische Methode für die Markierung von Membranproteinen an lebenden Zellen. Angewandte Chemie, 2014, 126, 10402-10406.	2.0	20
130	Semi-synthesis of chemokines. Current Opinion in Chemical Biology, 2014, 22, 100-107.	6.1	13
131	Matrix Metalloproteinase 9 (MMP-9) Mediated Release of MMP-9 Resistant Stromal Cell-Derived Factor 1α (SDF-1α) from Surface Modified Polymer Films. ACS Applied Materials & Interfaces, 2014, 6, 5891-5899.	8.0	27
132	Processing, signaling, and physiological function of chemerin. IUBMB Life, 2014, 66, 19-26.	3.4	116
133	Analysis of a rare functional truncating mutation rs61757459 in vaspin (SERPINA12) on circulating vaspin levels. Journal of Molecular Medicine, 2013, 91, 1285-1292.	3.9	6
134	Vaspin inhibits kallikrein 7 by serpin mechanism. Cellular and Molecular Life Sciences, 2013, 70, 2569-2583.	5.4	125
135	In vitro modification of substituted cysteines as tool to study receptor functionality and structure–activity relationships. Analytical Biochemistry, 2013, 439, 173-183.	2.4	3
136	Chemerin and Vaspin: Possible Targets to Treat Obesity?. ChemMedChem, 2013, 8, 549-559.	3.2	11
137	Large scale modification of biomolecules using immobilized sortase A from Staphylococcus aureus. Bioorganic and Medicinal Chemistry, 2013, 21, 3504-3510.	3.0	28
138	Photoactivatable Chemokines – Controlling Protein Activity by Light. Angewandte Chemie - International Edition, 2013, 52, 9550-9553.	13.8	30
139	Tuning peptide affinity for biofunctionalized surfaces. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 69-77.	4.3	12
140	Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement. Biochemical Journal, 2013, 452, 271-280.	3.7	47
141	Investigation of lysine side chain interactions of interleukin-8 with heparin and other glycosaminoglycans studied by a methylation-NMR approach. Glycobiology, 2013, 23, 1260-1269.	2.5	40
142	Highlight: Protein states with cell biological and medicinal relevance. Biological Chemistry, 2013, 394, 919-920.	2.5	0
143	Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors. Biological Chemistry, 2013, 394, 921-936.	2.5	37
144	The activity of prolactin releasing peptide correlates with its helicity. Biopolymers, 2013, 99, 314-325.	2.4	7

#	Article	IF	CITATIONS
145	Oxidative <i>in vitro</i> folding of a cysteine deficient variant of the G protein-coupled neuropeptide Y receptor type 2 improves stability at high concentration. Biological Chemistry, 2013, 394, 1045-1056.	2.5	18
146	The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin Secretion. PLoS ONE, 2013, 8, e54106.	2.5	49
147	Neuropeptide Y receptors: how to get subtype selectivity. Frontiers in Endocrinology, 2013, 4, 5.	3.5	124
148	Preparation of C-terminally Modified Chemokines by Expressed Protein Ligation. Methods in Molecular Biology, 2013, 1047, 103-118.	0.9	5
149	Specific mutations on the receptorâ€binding interface of nonâ€visual arrestins differently affect recruitment by the NPY receptor family. FASEB Journal, 2013, 27, 1031.3.	0.5	0
150	Imitation and modification of bioactive lead structures via integration of boron clusters. Pure and Applied Chemistry, 2012, 84, 2289-2298.	1.9	13
151	Ligand-mimicking Receptor Variant Discloses Binding and Activation Mode of Prolactin-releasing Peptide*. Journal of Biological Chemistry, 2012, 287, 32181-32194.	3.4	8
152	Onâ€Resin Synthesis of an Acylated and Fluorescence‣abeled Cyclic Integrin Ligand for Modification of Poly(lactic oâ€glycolic acid). Chemistry and Biodiversity, 2012, 9, 2648-2658.	2.1	7
153	Residue 75 of Interleukinâ€8 is Crucial for its Interactions with Glycosaminoglycans. ChemBioChem, 2012, 13, 2558-2566.	2.6	26
154	Design, Evaluation, and Comparison of Ghrelin Receptor Agonists and Inverse Agonists as Suitable Radiotracers for PET Imaging. Bioconjugate Chemistry, 2012, 23, 771-784.	3.6	30
155	An Aromatic Region To Induce a Switch between Agonism and Inverse Agonism at the Ghrelin Receptor. Journal of Medicinal Chemistry, 2012, 55, 7437-7449.	6.4	42
156	Selective Mode of Action of Guanidine-Containing Non-Peptides at Human NPFF Receptors. Journal of Medicinal Chemistry, 2012, 55, 6124-6136.	6.4	18
157	Peptides and peptide conjugates: therapeutics on the upward path. Future Medicinal Chemistry, 2012, 4, 1567-1586.	2.3	125
158	Biocompatible Silicon Surfaces through Orthogonal Click Chemistries and a High Affinity Silicon Oxide Binding Peptide. Bioconjugate Chemistry, 2012, 23, 2129-2137.	3.6	32
159	Molecular Tools to Characterize Adiponectin Activity. Vitamins and Hormones, 2012, 90, 31-56.	1.7	6
160	The anterograde transport of the human neuropeptide Y2 receptor is regulated by a subtype specific mechanism mediated by the C-terminus. Neuropeptides, 2012, 46, 335-343.	2.2	14
161	Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology, 2012, 22, 134-145.	2.5	120
162	Vaspin – a link of obesity and psoriasis?. Experimental Dermatology, 2012, 21, 309-312.	2.9	30

#	Article	IF	CITATIONS
163	Two motifs with different function regulate the anterograde transport of the adiponectin receptor 1. Cellular Signalling, 2012, 24, 1762-1769.	3.6	10
164	A novel, biased-like SDF-1 derivative acts synergistically with starPEG-based heparin hydrogels and improves eEPC migration in vitro. Journal of Controlled Release, 2012, 162, 68-75.	9.9	62
165	Genetically Encoded Photocrosslinkers as Molecular Probes To Study Gâ€Proteinâ€Coupled Receptors (GPCRs). Angewandte Chemie - International Edition, 2012, 51, 310-312.	13.8	15
166	Assessment of a Fully Active Class A G Protein-Coupled Receptor Isolated from <i>in Vitro</i> Folding. Biochemistry, 2011, 50, 9817-9825.	2.5	11
167	Long-Acting Lipidated Analogue of Human Pancreatic Polypeptide Is Slowly Released into Circulation. Journal of Medicinal Chemistry, 2011, 54, 2658-2667.	6.4	68
168	Incorporation of <i>ortho</i> -Carbaboranyl- <i>N</i> _ε -Modified <scp>l</scp> -Lysine into Neuropeptide Y Receptor Y ₁ - and Y ₂ -Selective Analogues. Journal of Medicinal Chemistry, 2011, 54, 2368-2377.	6.4	60
169	Adiponectin receptor 1 interacts with both subunits of protein kinase CK2. Molecular and Cellular Biochemistry, 2011, 356, 185-189.	3.1	9
170	Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. Journal of Peptide Science, 2011, 17, 233-246.	1.4	69
171	Asborin Inhibits Aldo/Keto Reductaseâ€1A1. ChemMedChem, 2011, 6, 89-93.	3.2	36
172	Palmitoylated SDF1â€Î± Shows Increased Resistance against Proteolytic Degradation in Liver Homogenates. ChemMedChem, 2011, 6, 193-200.	3.2	20
173	Structure–Activity Studies of RFamide Peptides Reveal Subtypeâ€Selective Activation of Neuropeptide FF1 and FF2 Receptors. ChemMedChem, 2011, 6, 1081-1093.	3.2	37
174	Simultaneous "One Pot―Expressed Protein Ligation and Cu ^I â€Catalyzed Azide/Alkyne Cycloaddition for Protein Immobilization. ChemBioChem, 2011, 12, 2426-2430.	2.6	16
175	Unique Interaction Pattern for a Functionally Biased Ghrelin Receptor Agonist. Journal of Biological Chemistry, 2011, 286, 20845-20860.	3.4	42
176	RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential. Pharmaceuticals, 2011, 4, 1248-1280.	3.8	60
177	Breastâ€Cancer Diagnosis by Neuropeptideâ€Y Analogues: From Synthesis to Clinical Application. Angewandte Chemie - International Edition, 2010, 49, 1155-1158.	13.8	76
178	Microscopic Mechanism of Specific Peptide Adhesion to Semiconductor Substrates. Angewandte Chemie - International Edition, 2010, 49, 9530-9533.	13.8	47
179	Identification of a potential modification site in human stromal cellâ€derived factorâ€1. Biopolymers, 2010, 94, 771-778.	2.4	18
180	A reconstitution protocol for the in vitro folded human G protein-coupled Y2 receptor into lipid environment. Biophysical Chemistry, 2010, 150, 29-36.	2.8	30

#	Article	IF	CITATIONS
181	Selective labelling of stromal cellâ€derived factor 1α with carboxyfluorescein to study receptor internalisation. Journal of Peptide Science, 2010, 16, 568-574.	1.4	11
182	Ligand-induced Internalization and Recycling of the Human Neuropeptide Y2 Receptor Is Regulated by Its Carboxyl-terminal Tail. Journal of Biological Chemistry, 2010, 285, 41578-41590.	3.4	39
183	Dimerization of adiponectin receptor 1 is inhibited by adiponectin. Journal of Cell Science, 2010, 123, 1320-1328.	2.0	39
184	Ghrelin Receptor. Methods in Enzymology, 2010, 485, 103-121.	1.0	49
185	Access to gram scale amounts of functional globular adiponectin from E. coli inclusion bodies by alkaline-shock solubilization. Biochemical and Biophysical Research Communications, 2010, 398, 32-37.	2.1	22
186	Peptide drugs to target G protein-coupled receptors. Trends in Pharmacological Sciences, 2010, 31, 434-441.	8.7	82
187	Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biological Chemistry, 2010, 391, 1005-18.	2.5	87
188	Type I Arginine Methyltransferases PRMT1 and PRMT-3 Act Distributively. Journal of Biological Chemistry, 2009, 284, 8274-8282.	3.4	41
189	Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization. Cellular Signalling, 2009, 21, 61-68.	3.6	29
190	Protein kinase CK2 interacts with adiponectin receptor 1 and participates in adiponectin signaling. Cellular Signalling, 2009, 21, 936-942.	3.6	51
191	Prokaryotic expression, in vitro folding, and molecular pharmacological characterization of the neuropeptide Y receptor type 2. Biotechnology Progress, 2009, 25, 1732-1739.	2.6	25
192	The interaction of neuropeptide Y with negatively charged and zwitterionic phospholipid membranes. European Biophysics Journal, 2009, 38, 663-677.	2.2	16
193	Ghrelin—a novel generation of antiâ€obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. Journal of Peptide Science, 2009, 15, 711-730.	1.4	43
194	First selective agonist of the neuropeptide Y ₁ â€receptor with reduced size. Journal of Peptide Science, 2009, 15, 856-866.	1.4	34
195	Illuminating the life of GPCRs. Cell Communication and Signaling, 2009, 7, 16.	6.5	66
196	Towards Understanding the Free and Receptor Bound Conformation of Neuropeptide Y by Fluorescence Resonance Energy Transfer Studies. Chemical Biology and Drug Design, 2009, 73, 573-583.	3.2	2
197	The neuropeptide Y monomer in solution is not folded in the pancreatic-polypeptide fold. Protein Science, 2009, 11, 1834-1844.	7.6	34
198	Synthesis and Application of Peptides as Drug Carriers. Methods in Molecular Biology, 2009, 535, 389-403.	0.9	7

#	Article	IF	CITATIONS
199	Generation of Carrier Peptides for the Delivery of Nucleic Acid Drugs in Primary Cells. ChemMedChem, 2008, 3, 241-253.	3.2	26
200	Microelectrode chip based real time monitoring of vital MCF-7 mamma carcinoma cells by impedance spectroscopy. Biosensors and Bioelectronics, 2008, 24, 253-259.	10.1	25
201	Calcitonin-derived peptide carriers: Mechanisms and application. Advanced Drug Delivery Reviews, 2008, 60, 485-498.	13.7	34
202	Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus. Cellular Signalling, 2008, 20, 1740-1749.	3.6	63
203	Molecular recognition of the NPY hormone family by their receptors. Nutrition, 2008, 24, 907-917.	2.4	64
204	Guanidineâ^'Acylguanidine Bioisosteric Approach in the Design of Radioligands: Synthesis of a Tritium-Labeled <i>N</i> ^G -Propionylargininamide ([³ H]-UR-MK114) as a Highly Potent and Selective Neuropeptide Y Y ₁ Receptor Antagonist. Journal of Medicinal Chemistry, 2008, 51, 8168-8172.	6.4	50
205	Structure and Dynamics of Helix-0 of the N-BAR Domain in Lipid Micelles and Bilayers. Biophysical Journal, 2008, 95, 4315-4323.	0.5	47
206	GPC Receptors and Not Ligands Decide the Binding Mode in Neuropeptide Y Multireceptor/Multiligand System. Biochemistry, 2008, 47, 5905-5914.	2.5	25
207	Pyridone Dipeptide Backbone Scan To Elucidate Structural Properties of a Flexible Peptide Segment. Journal of the American Chemical Society, 2008, 130, 8326-8336.	13.7	17
208	Novel Chemically Modified Analogues of Neuropeptide Y for Tumor Targeting. Bioconjugate Chemistry, 2008, 19, 1430-1438.	3.6	52
209	Artificial Chemokines: Combining Chemistry and Molecular Biology for the Elucidation of Interleukin-8 Functionality. Journal of the American Chemical Society, 2008, 130, 15311-15317.	13.7	72
210	Promiscuous Modification of the Nuclear Poly(A)-binding Protein by Multiple Protein-arginine Methyltransferases Does Not Affect the Aggregation Behavior. Journal of Biological Chemistry, 2008, 283, 20408-20420.	3.4	41
211	The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor. Journal of Biological Chemistry, 2008, 283, 33337-33346.	3.4	32
212	Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. Journal of Experimental Medicine, 2008, 205, 1435-1446.	8.5	66
213	Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 186-199.	1.7	53
214	Receptor Subtype-specific Docking of Asp6.59 with C-terminal Arginine Residues in Y Receptor Ligands. Journal of Biological Chemistry, 2007, 282, 7543-7551.	3.4	81
215	Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism. Journal of Biological Chemistry, 2007, 282, 15799-15811.	3.4	73

216 Multiple Peptide Synthesis to Identify Bioactive Hormone Structures. , 2007, , 243-288.

#	Article	IF	CITATIONS
217	Tracking of human Y receptors in living cells—A fluorescence approach. Peptides, 2007, 28, 226-234.	2.4	30
218	Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nuclear Medicine and Biology, 2007, 34, 17-28.	0.6	89
219	Determination of Affinity and Activity of Ligands at the Human Neuropeptide Y Y4Receptor by Flow Cytometry and Aequorin Luminescence. Journal of Receptor and Signal Transduction Research, 2007, 27, 217-233.	2.5	39
220	Specifically Immobilised Aldo/Keto Reductase AKR1A1 Shows a Dramatic Increase in Activity Relative to the Randomly Immobilised Enzyme. ChemBioChem, 2007, 8, 1071-1076.	2.6	43
221	Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability. Biopolymers, 2007, 88, 182-189.	2.4	16
222	One-step procedure for staining of proteins with ruthenium II tris (bathophenanthroline) Tj ETQq0 0 0 rgBT /Over	lock 10 Tf	50,542 Td (d
223	Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y2 receptors. European Journal of Neuroscience, 2007, 25, 1136-1143.	2.6	32
224	Proliferative Effect of Calcitonin Gene-related Peptide is Induced by at least Five Proteins as Identified by Proteome Profiling. Chemical Biology and Drug Design, 2007, 69, 14-22.	3.2	3
225	Identification of the dimerisation interface of human interleukin-8 by IL-8-variants containing the photoactivatable amino acid benzoyl-phenylalanine. European Biophysics Journal, 2007, 36, 385-391.	2.2	9
226	Molecular ligand-receptor interaction of the NPY/PP peptide family. , 2006, , 35-62.		5
227	Localization of Novel Adiponectin Receptor Constructs. Journal of Receptor and Signal Transduction Research, 2006, 26, 647-657.	2.5	20
228	Identification of the Key Residue of Calcitonin Gene Related Peptide (CGRP) 27â^'37 to Obtain Antagonists with Picomolar Affinity at the CGRP Receptor. Journal of Medicinal Chemistry, 2006, 49, 616-624.	6.4	36
229	Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the Receptor. Molecular Pharmacology, 2006, 70, 936-946.	2.3	82
230	Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 347-354.	2.6	67
231	Structural properties of orexins for activation of their receptors. Journal of Peptide Science, 2006, 12, 258-266.	1.4	20
232	Isotope-labeled cross-linkers and fourier transform ion cyclotron resonance mass spectrometry for structural analysis of a protein/peptide complex. Journal of the American Society for Mass Spectrometry, 2006, 17, 1100-1113.	2.8	72
233	Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands. European Journal of Pharmacology, 2006, 551, 10-18.	3.5	36
234	Glutamate release by neurons evokes a purinergic inhibitory mechanism of osmotic glial cell swelling in the rat retina: Activation by neuropeptide Y. Journal of Neuroscience Research, 2006, 83, 538-550.	2.9	93

#	Article	IF	CITATIONS
235	Structure-Activity Relationship Studies: Methods and Ligand Design for G-Protein Coupled Peptide Receptors. Current Protein and Peptide Science, 2006, 7, 335-353.	1.4	7
236	Neuropeptide Y stimulates neuronal precursor proliferation in the postâ€natal and adult dentate gyrus. Journal of Neurochemistry, 2005, 93, 560-570.	3.9	174
237	The antiâ€epileptic actions of neuropeptide Y in the hippocampus are mediated by Y ₂ and not Y ₅ receptors. European Journal of Neuroscience, 2005, 22, 1417-1430.	2.6	114
238	Expressed Protein Ligation to Obtain Selectively Modified Aldo/Keto Reductases. Protein and Peptide Letters, 2005, 12, 777-781.	0.9	4
239	Expressed Protein Ligation for Protein Semisynthesis and Engineering. , 2005, 298, 105-130.		6
240	Strongly Altered Receptor Binding Properties in PP and NPY Chimeras Are Accompanied by Changes in Structure and Membrane Binding,. Biochemistry, 2005, 44, 9255-9264.	2.5	27
241	Bilayer interaction and localization of cell penetrating peptides with model membranes: A comparative study of a human calcitonin (hCT)-derived peptide with pVEC and pAntp(43–58). Biochimica Et Biophysica Acta - Biomembranes, 2005, 1712, 197-211.	2.6	26
242	Membrane interaction of neuropeptide Y detected by EPR and NMR spectroscopy. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1714, 103-113.	2.6	24
243	Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors. Regulatory Peptides, 2005, 124, 163-172.	1.9	53
244	Decoding the Entry of Two Novel Cell-Penetrating Peptides in HeLa Cells:Â Lipid Raft-Mediated Endocytosis and Endosomal Escapeâ€. Biochemistry, 2005, 44, 72-81.	2.5	129
245	Membrane Surface-Associated Helices Promote Lipid Interactions and Cellular Uptake of Human Calcitonin-Derived Cell Penetrating Peptides. Biophysical Journal, 2005, 89, 4056-4066.	0.5	33
246	From Transcription Profile to Expression: The Signaling Repertoire of the SK-N-MC Neuroepithelioma Cell-Line. Journal of Receptor and Signal Transduction Research, 2004, 24, 257-282.	2.5	9
247	Expressed protein ligation. FEBS Journal, 2004, 271, 663-677.	0.2	135
248	Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes. Neuropeptides, 2004, 38, 153-161.	2.2	11
249	Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1–7), NPY(19–23), Ala31, Aib32, Gln34]hPP. Neuropeptides, 2004, 38, 163-174.	2.2	30
250	Cellular Internalization of Human Calcitonin Derived Peptides in MDCK Monolayers: A Comparative Study with Tat(47-57) and Penetratin(43-58). Pharmaceutical Research, 2004, 21, 33-42.	3.5	37
251	Cellular Uptake But Low Permeation of Human Calcitonin-Derived Cell Penetrating Peptides and Tat(47-57) Through Well-Differentiated Epithelial Models. Pharmaceutical Research, 2004, 21, 1248-1256.	3.5	59
252	Site specific biotinylation of the human aldo/keto reductase AKR1A1 for immobilization. Tetrahedron, 2004, 60, 7507-7513.	1.9	8

#	Article	IF	CITATIONS
253	In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 51-54.	2.2	42
254	Structural Investigations of a Human Calcitonin-Derived Carrier Peptide in a Membrane Environment by Solid-State NMRâ€. Biochemistry, 2004, 43, 12459-12468.	2.5	14
255	Structureâ ^{°°} Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands. Journal of Medicinal Chemistry, 2004, 47, 1153-1160.	6.4	74
256	Interactions of the Human Calcitonin Fragment 9–32 with Phospholipids: A Monolayer Study. Biophysical Journal, 2004, 87, 386-395.	0.5	30
257	Improving the Tumor Uptake of 99mTc-Labeled Neuropeptides Using Stabilized Peptide Analogues. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 181-188.	1.0	24
258	Calcitonin-derived carrier peptide plays a major role in the membrane localization of a peptide-cargo complex. FEBS Letters, 2004, 569, 346-350.	2.8	8
259	Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regulatory Peptides, 2004, 120, 205-214.	1.9	36
260	Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47–57) and penetratin(43–58). Biochemical Journal, 2004, 382, 945-956.	3.7	68
261	Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments. Journal of Molecular Recognition, 2003, 16, 280-287.	2.1	31
262	Neuropeptid-Y-Analoga mit β-Aminocyclopropancarbonsäre-Einheiten sind die kürzesten linearen und selektiven Peptide am Y1-Rezeptor. Angewandte Chemie, 2003, 115, 212-215.	2.0	18
263	Semisynthesis and Characterization of the First Analogues of Pro-Neuropeptide Y. ChemBioChem, 2003, 4, 425-433.	2.6	20
264	Expressed Enzymatic Ligation for the Semisynthesis of Chemically Modified Proteins. Angewandte Chemie - International Edition, 2003, 42, 4916-4918.	13.8	31
265	Analogues of Neuropeptide Y Containing β-Aminocyclopropane Carboxylic Acids are the Shortest Linear Peptides That Are Selective for the Y1 Receptor. Angewandte Chemie - International Edition, 2003, 42, 202-205.	13.8	79
266	Peptide αthioester formation using standard Fmoc-chemistry. Tetrahedron Letters, 2003, 44, 3551-3554.	1.4	85
267	Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. Journal of Neurochemistry, 2003, 86, 646-659.	3.9	166
268	Nanoâ€highâ€performance liquid chromatography in combination with nanoâ€electrospray ionization Fourier transform ionâ€cyclotron resonance mass spectrometry for proteome analysis. Rapid Communications in Mass Spectrometry, 2003, 17, 1240-1246.	1.5	27
269	Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125 l][hPP1-17 , Ala31 , Aib32]NPY. British Journal of Pharmacology, 2003, 139, 1360-1368.	5.4	11
270	Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. British Journal of Pharmacology, 2003, 139, 1433-1440.	5.4	40

#	Article	IF	CITATIONS
271	Neuropeptide Y (NPY) Suppresses Experimental Autoimmune Encephalomyelitis: NPY1 Receptor-Specific Inhibition of Autoreactive Th1 Responses In Vivo. Journal of Immunology, 2003, 171, 3451-3458.	0.8	103
272	Facile and Selective Nanoscale Labeling of Peptides in Solution by Using Photolabile Protecting Groups. Journal of Medicinal Chemistry, 2003, 46, 4369-4372.	6.4	25
273	Presence of neuropeptide Y and the Y1 receptor in the plasma membrane and nuclear envelope of human endocardial endothelial cells: modulation of intracellular calcium. Canadian Journal of Physiology and Pharmacology, 2003, 81, 288-300.	1.4	50
274	Semisynthesis and Application of Carboxyfluorescein-Labelled Biologically Active Human Interleukin-8. Biological Chemistry, 2003, 384, 1619-30.	2.5	26
275	Homodimerization of Neuropeptide Y Receptors Investigated by Fluorescence Resonance Energy Transfer in Living Cells. Journal of Biological Chemistry, 2003, 278, 10562-10571.	3.4	117
276	A Y2 Receptor Mimetic Aptamer Directed against Neuropeptide Y. Journal of Biological Chemistry, 2002, 277, 11416-11422.	3.4	34
277	Neuropeptide Y1 and Y5 Receptors Mediate the Effects of Neuropeptide Y on the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology, 2002, 143, 4513-4519.	2.8	75
278	Multiple NPY Receptors Inhibit GABAA Synaptic Responses of Rat Medial Parvocellular Effector Neurons in the Hypothalamic Paraventricular Nucleus. Endocrinology, 2002, 143, 535-543.	2.8	55
279	Anthrax: Terror im Immunsystem. Nachrichten Aus Der Chemie, 2002, 50, 42-45.	0.0	1
280	Key Motif to Gain Selectivity at the Neuropeptide Y5-Receptor:Â Structure and Dynamics of Micelle-Bound [Ala31, Pro32]-NPYâ€,‡. Biochemistry, 2002, 41, 8031-8042.	2.5	17
281	Ala31-Aib32:Â Identification of the Key Motif for High Affinity and Selectivity of Neuropeptide Y at the Y5-Receptorâ€. Biochemistry, 2002, 41, 8043-8049.	2.5	28
282	Biochemical Characterisation and Genetic Analysis of Aureocin A53, a New, Atypical Bacteriocin from Staphylococcus aureus. Journal of Molecular Biology, 2002, 319, 745-756.	4.2	104
283	In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nuclear Medicine and Biology, 2002, 29, 553-560.	0.6	98
284	Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). Journal of Neuroimmunology, 2002, 129, 35-42.	2.3	46
285	NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. Journal of Neuroimmunology, 2002, 132, 25-33.	2.3	43
286	Tetrafunctional Photoaffinity Labels Based on Nakanishi'sm-Nitroalkoxy-Substituted Phenyltrifluoromethyldiazirine. Angewandte Chemie - International Edition, 2002, 41, 2293-2297.	13.8	22
287	Cellular Internalization of Enhanced Green Fluorescent Protein Ligated to a Human Calcitonin-Based Carrier Peptide. ChemBioChem, 2002, 3, 672.	2.6	49
288	The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor. FEBS Journal, 2002, 269, 1128-1135.	0.2	27

#	Article	IF	CITATIONS
289	Electron paramagnetic resonance backbone dynamics studies on spin-labelled neuropeptide Y analogues. Journal of Peptide Science, 2002, 8, 671-682.	1.4	33
290	Blockade of neuropeptide Y ₂ receptors and suppression of NPY's antiâ€epileptic actions in the rat hippocampal slice by BIIE0246. British Journal of Pharmacology, 2002, 136, 502-509.	5.4	47
291	The First Reporter Gene Assay on Living Cells Green Fluorescent Protein as Reporter Gene for the Investigation of Gi-Protein Coupled Receptors. Molecular Biotechnology, 2002, 21, 009-018.	2.4	11
292	Structure and Dynamics of Micelle-bound Neuropeptide Y: Comparison with Unligated NPY and Implications for Receptor Selection. Journal of Molecular Biology, 2001, 305, 307-329.	4.2	129
293	Y-receptor affinity modulation by the design of pancreatic polypeptide/neuropeptide Y chimera led to Y5-receptor ligands with picomolar affinity. Peptides, 2001, 22, 365-378.	2.4	39
294	99mTc-Labeled Neuropeptide Y Analogues as Potential Tumor Imaging Agents. Bioconjugate Chemistry, 2001, 12, 1028-1034.	3.6	63
295	Novel analogues of neuropeptide Y with a preference for the Y1-receptor. FEBS Journal, 2001, 268, 2828-2837.	0.2	88
296	Biophysical methods to study ligand-receptor interactions of neuropeptide Y. Biopolymers, 2001, 60, 420-437.	2.4	30
297	Novel Peptide Conjugates for Tumor-Specific Chemotherapy§. Journal of Medicinal Chemistry, 2001, 44, 1341-1348.	6.4	96
298	Characterisation of G-Protein-coupled Receptors by Antibodies. Current Medicinal Chemistry, 2000, 7, 897-910.	2.4	10
299	Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. , 2000, 6, 97-122.		176
300	On the synthesis of orexin A: a novel one-step procedure to obtain peptides with two intramolecular disulphide bonds. Journal of Peptide Science, 2000, 6, 387-397.	1.4	29
301	Monitoring of the internalization of neuropeptideâ $∈f$ Y on neuroblastoma cell line SK-N-MC. FEBS Journal, 2000, 267, 5631-5637.	0.2	47
302	Neuropeptide Y5 Receptors Reduce Synaptic Excitation in Proximal Subiculum, But Not Epileptiform Activity in Rat Hippocampal Slices. Journal of Neurophysiology, 2000, 83, 723-734.	1.8	49
303	The First Selective Agonist for the Neuropeptide YY5Receptor Increases Food Intake in Rats. Journal of Biological Chemistry, 2000, 275, 36043-36048.	3.4	167
304	2–36[K4,RYYSA19–23]PP a novel Y5-receptor preferring ligand with strong stimulatory effect on food intake. Regulatory Peptides, 2000, 87, 47-58.	1.9	42
305	Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides, 2000, 21, 1885-1893.	2.4	19
306	Comparison of Antibodies Directed Against Receptor Segments of NPY-Receptors. Journal of Receptor and Signal Transduction Research, 1999, 19, 379-394.	2.5	10

#	Article	IF	CITATIONS
307	CGRP 27–37 analogues with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. Regulatory Peptides, 1999, 79, 153-158.	1.9	26
308	Amino Acid Side Chain Attachment Approach and Its Application to the Synthesis of Tyrosine-Containing Cyclic Peptides. Journal of Organic Chemistry, 1999, 64, 4353-4361.	3.2	68
309	Molecular Characterization of the Human Neuropeptide Y Y ₂ -Receptor. Biochemistry, 1999, 38, 6897-6902.	2.5	22
310	Molecular Characterization of the Ligand-Receptor Interaction of Neuropeptide Y. Current Medicinal Chemistry, 1999, 6, 1055-1066.	2.4	20
311	Translocation of Human Calcitonin in Respiratory Nasal Epithelium Is Associated with Self-Assembly in Lipid Membrane. Biochemistry, 1998, 37, 16582-16590.	2.5	82
312	Probing of the neuropeptide Y-Y1-receptors interaction with anti-receptor antibodies. FEBS Journal, 1998, 255, 595-603.	0.2	19
313	Y1 receptors in the nucleus accumbens: Ultrastructural localization and association with neuropeptide Y. , 1998, 52, 54-68.		40
314	A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 597-600.	2.2	87
315	Structure–activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems. Regulatory Peptides, 1998, 75-76, 3-8.	1.9	11
316	From Micromolar to Nanomolar Affinity:Â A Systematic Approach To Identify the Binding Site of CGRP at the Human Calcitonin Gene-Related Peptide 1 Receptorâ€. Journal of Medicinal Chemistry, 1998, 41, 117-123.	6.4	61
317	Fluorescent Labelled Analogues of Neuropeptide Y for the Characterization of Cells Expressing NPY Receptor Subtypes. Journal of Receptor and Signal Transduction Research, 1997, 17, 407-418.	2.5	22
318	Role of Prohormone Convertases in Pro-Neuropeptide Y Processing:  Coexpression and in Vitro Kinetic Investigations. Biochemistry, 1997, 36, 16309-16320.	2.5	51
319	Overlapping Gene Structure of the Human Neuropeptide Y Receptor Subtypes Y1 and Y5 Suggests Coordinate Transcriptional Regulation. Genomics, 1997, 41, 315-319.	2.9	114
320	The Bioactive Conformation of Neuropeptide Y Analogues at the Human Y2-Receptor. FEBS Journal, 1997, 247, 1019-1028.	0.2	16
321	Comparison of the photochemical behavior of four different photoactivatable probes. Chemical Biology and Drug Design, 1997, 49, 375-383.	1.1	91
322	BIBP 3226, a potent and selective neuropeptide Y Y1-receptor antagonist. Structure-activity studies and localization of the human Y1 receptor binding site. , 1997, , 175-XX.		13
323	Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and Câ€ŧerminal NPY analogues. British Journal of Pharmacology, 1996, 117, 325-332.	5.4	21
324	Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist. Regulatory Peptides, 1996, 65, 61-70.	1.9	23

#	Article	IF	CITATIONS
325	Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y ₂ receptor. FEBS Letters, 1996, 394, 169-173.	2.8	40
326	Structural characterization and binding sites of G-protein-coupled receptors. Drug Discovery Today, 1996, 1, 502-513.	6.4	69
327	Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers, 1995, 37, 123-142.	2.4	127
328	A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor. Journal of Peptide Science, 1995, 1, 341-348.	1.4	30
329	Synthesis, Receptor Binding, and Crosslinking of Photoactive Analogues of Neuropeptide Y. Journal of Receptor and Signal Transduction Research, 1995, 15, 473-485.	2.5	6
330	Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. Molecular and Cellular Endocrinology, 1995, 112, 215-222.	3.2	50
331	Complete L-Alanine Scan of Neuropeptide Y Reveals Ligands Binding to Y1 and Y2 Receptors with Distinguished Conformations. FEBS Journal, 1994, 225, 947-958.	0.2	167
332	The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. European Journal of Pharmacology, 1994, 271, R11-R13.	3.5	343
333	High-affinity analogues of neuropeptide Y containing conformationally restricted non-proteinogenic amino acids. Biochemical Society Transactions, 1994, 22, 145-149.	3.4	19
334	Novel Y2-selective, reduced-size agonists of neuropeptide Y. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 937-942.	2.2	9
335	Natural and synthetic peptide pools: Characterization by sequencing and electrospray mass spectrometry. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 431-436.	2.2	28
336	Optimization of capillary electrophoresis of mixtures of basic peptides and comparison with HPLC. Analytical Chemistry, 1993, 65, 1399-1405.	6.5	50
337	Cyclopeptide Analogs for Characterization of the Neuropeptide Y Y2-receptor. Journal of Receptors and Signal Transduction, 1993, 13, 215-228.	1.2	5
338	Characterization of the binding site of neuropeptide Y to the rabbit kidney receptor using multiple peptide synthesis. Biochemical Society Transactions, 1992, 20, 847-850.	3.4	10
339	A novel cyclic analog of neuropeptide Y specific for the Y2 receptor. FEBS Journal, 1992, 206, 957-964.	0.2	54
340	Multiple Peptide Synthesis Methods and Their Applications. New Synthetic Methods(87). Angewandte Chemie International Edition in English, 1992, 31, 367-383.	4.4	284
341	Antibody binding to a collagen type-II epitope gives rise to an inhibitory peptide for autoreactive T cells. European Journal of Immunology, 1992, 22, 1063-1067.	2.9	16
342	Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides. Molecular Immunology, 1991, 28, 1225-1232.	2.2	105

#	Article	IF	CITATIONS
343	α-Helical small molecular size analogues of neuropeptide Y: Structure-activity relationships. Biopolymers, 1991, 31, 613-619.	2.4	27
344	Sulfonation of arginine residues as side reaction in Fmocâ€peptide synthesis. International Journal of Peptide and Protein Research, 1991, 38, 25-31.	0.1	31
345	Cleavage kinetics and anchor linked intermediates in solid phase peptide amide synthesis. International Journal of Peptide and Protein Research, 1991, 38, 146-153.	0.1	17
346	Structure/activity relationships of C-terminal neuropeptide Y peptide segments and analogues composed of sequence 1-4 linked to 25-36. FEBS Journal, 1990, 194, 449-456.	0.2	46
347	Biosynthesis of the lantibiotic Pep5. Isolation and characterization of a prepeptide containing dehydroamino acids. FEBS Journal, 1990, 194, 217-223.	0.2	111
348	Neuropeptide Y: identification of the binding site. International Journal of Peptide and Protein Research, 1990, 36, 522-530.	0.1	49
349	Protease-Triggered Release of Stabilized CXCL12 from Coated Biomaterials for Improved Implant Integration and Wound Healing. SSRN Electronic Journal, 0, , .	0.4	Ο